|
99
|
360
|
5idpA |
Cdk8-cycc in complex with (3-amino-1h-indazol-5-yl)-[(s)-2-(4-fluoro-phenyl)-piperidin-1-yl]-methanone |
|
104
|
365
|
5i5zA |
Cdk8-cycc in complex with 8-(1-methyl-2,2-dioxo-2,3-dihydro-1h-2l6-benzo[c]isothiazol-5-yl)-[1,6]naphthyridine-2-carboxylic acid methylamide |
|
104
|
362
|
5icpA |
Cdk8-cycc in complex with [(s)-2-(4-chloro-phenyl)-pyrrolidin-1-yl]-(5-methyl-imidazo[5,1-b][1,3,4]thiadiazol-2-yl)-methanone |
|
78
|
292
|
5hq0A |
Ternary complex of human proteins cdk1, cyclin b and cks2, bound to an inhibitor |
|
94
|
363
|
5hbjA |
Cdk8-cycc in complex with 8-[2-amino-3-chloro-5-(1-methyl-1h-indazol-5-yl)-pyridin-4-yl]-2,8-diaza-spiro[4.5]decan-1-one |
|
85
|
319
|
6gzhA |
Crystal structure of human cdk9/cyclint1 with a86 |
|
86
|
303
|
6ckxA |
Structure of cdk12/cyck in complex with a small molecule inhibitor n-(4-(1-methyl-1h-pyrazol-4-yl)phenyl)-n-((1r,4r)-4-(quinazolin-2-ylamino)cyclohexyl)acetamide |
|
94
|
320
|
6b3eA |
Crystal structure of human cdk12/cyclink in complex with an inhibitor |
|
82
|
282
|
6athA |
Cdk2/cyclin a/p27-kid-deltac |
|
118
|
366
|
5xs2A |
Cdk8-cycc in complex with compound 17:3-chloro-4-(4-pyridyl)-1h-pyrrole-2-carboxamide |
|
93
|
364
|
5bnjA |
Cdk8/cycc in complex with 8-{3-chloro-5-[4-(1-methyl-1h-pyrazol-4-yl)-phenyl]-pyridin- 4-yl}-2,8-diaza-spiro[4.5]decan-1-one |
|
81
|
296
|
5a14A |
Human cdk2 with type ii inhibitor |
|
70
|
318
|
4un0C |
Crystal structure of the human cdk12-cyclink complex |
|
95
|
360
|
4f70A |
Crystal structure of human cdk8/cycc in complex with compound 4 (1-[3-tert-butyl-1-(4-methylphenyl)-1h-pyrazol-5-yl]-3-[2-(morpholin-4-yl)ethyl]urea) |
|
99
|
360
|
4f6sA |
Crystal structure of human cdk8/cycc in complex with compound 7 (1-[3-tert-butyl-1-(4-methylphenyl)-1h-pyrazol-5-yl]urea) |
|
82
|
298
|
4ez3A |
Cdk2 in complex with nsc 134199 |
|
95
|
359
|
4f7jA |
Crystal structure of human cdk8/cycc in complex with compound 3 (1-[3-tert-butyl-1-(4-methylphenyl)-1h-pyrazol-5-yl]-3-(2-hydroxyethyl)urea) |
|
100
|
362
|
4f7nA |
Crystal structure of human cdk8/cycc in complex with compound 11 (1-[3-tert-butyl-1-(4-methylphenyl)-1h-pyrazol-5-yl]-3-(5-hydroxypentyl)urea) |
|
77
|
302
|
4ez7A |
Cdk2 in complex with staurosporine and 2 molecules of 8-anilino-1-naphthalene sulfonic acid |
|
65
|
291
|
4ez5A |
Cdk6 (monomeric) in complex with inhibitor |
|
104
|
361
|
4f6uA |
Crystal structure of human cdk8/cycc in complex with compound 5 (1-[3-tert-butyl-1-(4-methylphenyl)-1h-pyrazol-5-yl]-3-[3-(morpholin-4-yl)propyl]urea) |
|
91
|
361
|
4f7lA |
Crystal structure of human cdk8/cycc in complex with compound 2 (tert-butyl [3-({[3-tert-butyl-1-(4-methylphenyl)-1h-pyrazol-5-yl]carbamoyl}amino)propyl]carbamate) |
|
103
|
359
|
4f7sA |
Crystal structure of human cdk8/cycc in the dmg-in conformation |
|
101
|
359
|
4f6wA |
Crystal structure of human cdk8/cycc in complex with compound 1 (n-[3-tert-butyl-1-(4-methylphenyl)-1h-pyrazol-5-yl]-4-[2-({[3-tert-butyl-1-(4-methylphenyl)-1h-pyrazol-5-yl]carbamoyl}amino)ethyl]piperazine-1-carboxamide) |
|
87
|
298
|
4ek5A |
Crystal structure of the cdk2 in complex with aminopyrazole inhibitor |
|
86
|
300
|
4eojA |
Thr 160 phosphorylated cdk2 h84s, q85m, k89d - human cyclin a3 complex with atp |
|
85
|
299
|
4eooA |
Thr 160 phosphorylated cdk2 q131e - human cyclin a3 complex with atp |
|
80
|
298
|
4ek8A |
Crystal structure of the cdk2 in complex with thiazolylpyrimidine inhibitor |
|
87
|
321
|
4ec9A |
Crystal structure of full-length cdk9 in complex with cyclin t |
|
85
|
298
|
4erwA |
Cdk2 in complex with staurosporine |
|
84
|
299
|
4eoqA |
Thr 160 phosphorylated cdk2 wt - human cyclin a3 complex with atp |
|
86
|
298
|
4eokA |
Thr 160 phosphorylated cdk2 h84s, q85m, k89d - human cyclin a3 complex with the inhibitor nu6102 |
|
78
|
298
|
4ek6A |
Crystal structure of the cdk2 in complex with aminopyrazole inhibitor |
|
87
|
300
|
4eosA |
Thr 160 phosphorylated cdk2 wt - human cyclin a3 complex with the inhibitor ro3306 |
|
86
|
296
|
4ek4A |
Crystal structure of the cdk2 in complex with aminopyrazole inhibitor |
|
88
|
333
|
4ec8A |
Structure of full length cdk9 in complex with cyclint and drb |
|
85
|
300
|
4eonA |
Thr 160 phosphorylated cdk2 h84s, q85m, q131e - human cyclin a3 complex with the inhibitor ro3306 |
|
85
|
299
|
4eoiA |
Thr 160 phosphorylated cdk2 k89d, q131e - human cyclin a3 complex with the inhibitor ro3306 |
|
82
|
298
|
4eorA |
Thr 160 phosphorylated cdk2 wt - human cyclin a3 complex with the inhibitor nu6102 |
|
88
|
298
|
4eolA |
Thr 160 phosphorylated cdk2 h84s, q85m, k89d - human cyclin a3 complex with the inhibitor ro3306 |
|
87
|
296
|
4ek3A |
Crystal structure of apo cdk2 |
|
91
|
300
|
4eopA |
Thr 160 phosphorylated cdk2 q131e - human cyclin a3 complex with the inhibitor ro3306 |
|
83
|
299
|
4eomA |
Thr 160 phosphorylated cdk2 h84s, q85m, q131e - human cyclin a3 complex with atp |
|
82
|
296
|
4d1xA |
Cdk2 in complex with luciferin |
|
74
|
293
|
4d1zA |
Cdk2 in complex with a luciferin derivate |
|
80
|
333
|
4cxaA |
Crystal structure of the human cdk12-cyclin k complex bound to amppnp |
|
105
|
362
|
4crlA |
Crystal structure of human cdk8-cyclin c in complex with cortistatin a |
|
80
|
299
|
4cfxA |
Structure-based design of c8-substituted o6-cyclohexylmethoxyguanine cdk1 and 2 inhibitors. |
|
86
|
300
|
4cfwA |
Structure-based design of c8-substituted o6-cyclohexylmethoxyguanine cdk1 and 2 inhibitors. |
|
87
|
297
|
4cfmA |
Structure-based design of c8-substituted o6-cyclohexylmethoxyguanine cdk1 and 2 inhibitors. |
